S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 112-113
10.1097/01.hs9.0000843736.56298.a7